Vera Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
VERA$30.61+2.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share amounts)
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| (unaudited) | ||
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $55,090 | $92,646 |
| Marketable securities | 534,744 | 548,206 |
| Prepaid expenses and other assets, current | 16,242 | 10,366 |
| Total current assets | 606,076 | 651,218 |
| Property and equipment, net | 1,062 | 960 |
| Operating lease right-of-use assets | 2,915 | 3,372 |
| Prepaid expenses and other assets, noncurrent | 114 | 131 |
| Total assets | $610,167 | $655,681 |
| Liabilities and stockholders’ equity | ||
| Current liabilities: | ||
| Accounts payable | $9,262 | $7,665 |
| Operating lease liabilities | 1,191 | 1,483 |
| Accrued expenses and other liabilities, current | 11,441 | 16,223 |
| Total current liabilities | 21,894 | 25,371 |
| Long-term debt | 50,908 | 50,687 |
| Operating lease liabilities, noncurrent | 2,366 | 2,468 |
| Total liabilities | 75,168 | 78,526 |
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value; 10,000,000 authorized as of March 31, 2025 and December 31, 2024; no shares issued and outstanding as of March 31, 2025 and December 31, 2024 | — | — |
| Class A common stock, $0.001 par value; 500,000,000 shares authorized as of March 31, 2025 and December 31, 2024; 63,774,158 and 63,559,858 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 64 | 64 |
| Additional paid-in capital | 1,047,225 | 1,037,948 |
| Accumulated other comprehensive income | 654 | 393 |
| Accumulated deficit | (512,944) | (461,250) |
| Total stockholders’ equity | 534,999 | 577,155 |
| Total liabilities and stockholders’ equity | $610,167 | $655,681 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.